Despite the recent inclement weather, works at Queensland biotechnology company Vaxxas’ new Northshore facility are on track for completion in Q1-2023.

The project, which includes refurbishing an existing warehouse to create Australia’s first needle-free vaccine facility, will enable Vaxxas to manufacture its proprietary high-density microarray patch (HD-MAP) for Phase II, Phase III and early-stage commercial use.

The world-leading technology uses a small patch with a surface of thousands of micro-projections coated with a vaccine to deliver the vaccine to the abundance of immune cells immediately below the skin surface.

It has the potential to simplify vaccine distribution globally by eliminating the need for cold-chain storage and making administration quicker and easier.

Once home to airport parking, the 4000sqm structure has been stripped back to form the custom-built, single level facility that will house office, R&D laboratories, device and cleanroom manufacturing spaces.

When construction is finished, the facility is expected to manufacture millions of HD-MAPs for local and export use contributing significant dollars to the Queensland economy.

Up to 110 highly-skilled biomedical experts will make Vaxxas Northshore their home with the potential to welcome more staff over five years.

Founded in 2011 based on research at the University of Queensland, Vaxxas has achieved remarkable growth. It is the latest tenant to be joining the vibrant, waterfront Northshore precinct which has long been a hub for Queensland innovation and business.